Oxaliplatin + 5-Fluorouracil/Leucovorin

DRUG4 trials

Sponsors

Sanofi, First Affiliated Hospital of Zhejiang University, Kaohsiung Medical University Chung-Ho Memorial Hospital, Zhai Wenlong

Conditions

Bile Duct CarcinomaBiliary Tract CancerCarcinoma, HepatocellularCholangiocarcinomaGC/GEJCGall Bladder CancerMalignant Biliary Tract Tumors

Phase 1

Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma

Not yet recruitingNCT07680569

Kaohsiung Medical University Chung-Ho Memorial HospitalGC/GEJC

Start: 2026-06-01End: 2027-12-01Target: 40Updated: 2026-07-02

Phase 2

Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer

RecruitingNCT07025174

First Affiliated Hospital of Zhejiang UniversityBile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer +1

Start: 2025-06-01End: 2027-12-31Target: 60Updated: 2025-06-17

Phase 3

Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients

CompletedNCT00471965

SanofiCarcinoma, Hepatocellular

Start: 2007-03-31End: 2010-03-31Updated: 2010-09-20

Phase 4

A Prospective, Open-Label, Randomized Controlled Clinical Study Comparing Hepatic Arterial Infusion Chemotherapy (HAIC) With Capecitabine as Adjuvant Therapy After Radical Surgery for Malignant Biliary Tract Tumors

Not yet recruitingNCT07790445

Zhai WenlongMalignant Biliary Tract Tumors

Start: 2026-07-30End: 2028-12-31Target: 90Updated: 2026-08-27

Related Papers

Comprehensive Consideration before the Decision-Making of the Systemic Treatment in Patients with Advanced Hepatocellular Carcinoma

Liver Cancer2019-10-166 citations

Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.

2014-09-1573 citations